PATH | VRL
Menu

Safety and Immunogenicity of the Oral, Inactivated, Enterotoxigenic Escherichia coli Vaccine ETVAX in Bangladeshi Children and Infants: A Double-Blind, Randomised, Placebo-Controlled Phase 1/2 Trial

This article, published in The Lancet Infectious Diseases, reports the results of a study that examined the safety and immunogenicity of an enterotoxigenic Escherichia coli (ETEC) vaccine candidate with or without an adjuvant in Bangladeshi infants and children. The results showed that the vaccine candidate was safe and immunogenic, and the adjuvant enhanced immune responses. These results support further assessment of this vaccine candidate to determine protective efficacy in children in ETEC-endemic areas.

Author: Qadri F, Akhtar M, Bhuiyan TR, et al.

Published: 2019

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Qadri F, Akhtar M, Bhuiyan TR, et al. Safety and Immunogenicity of the Oral, Inactivated, Enterotoxigenic Escherichia coli Vaccine ETVAX in Bangladeshi Children and Infants: A Double-Blind, Randomised, Placebo-Controlled Phase 1/2 Trial. The Lancet Infectious Diseases. 2019;20(2):208-219.

Resource types: Peer-reviewed journal

Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)

Topics: Vaccine safety and performance, Disease/vaccine specific information, Vaccine stabilization and formulation

Regions: Asia